To assess possible roles of the renal kallikrein-kinin system in the development of renal impairments in diabetes mellitus, we determined daily excretion of urinary total and active kallikrein in uninephrectomized Wistar-Kyoto rats made diabetic by streptozotocin (45 mg/kg) as a bolus injection. We also evaluated the effect of captopril (50 mg/kg/day) administered orally on the development of diabetic renal impairments in the streptozotocin-treated rats. Active kallikrein was determined by its kininogenase activity, and generated kinins were radioimmunologically measured. Total kallikrein was also determined by measuring kininogenase activity after inactive kallikrein had been activated with trypsin (200,ag/ml). Urinary active kallikrein excretion was significantly reduced in streptozotocin-treated rats whereas urinary total kallikrein excretion was unchanged, resulting in the decreased ratio of active to total kallikrein compared to that in the controls. These reductions were preceded by the increased excretion of urine protein measured as an ilidex of renal impairments. The administration of captopril for 12 weeks attenuated the development of diabetic renal impairments evaluated by urine protein excretion in streptozotocin-treated rats, although it did not induce significant changes in urinary total and active kallikrein excretion, and the ratio of active to total kallikrein. Thus the results of this study indicate that the renal kallikrein-kinin system might not play major roles in the development of diabetic renal impairments in the rat, although the pathophysiological relevance of impaired activation of renal kallikrein system to the development of diabetic renal impairments remains to be determined. In addition, they suggest that the renoprotective effects of captopril may , be independent of the activation of renal kallikrein system in streptozotocin-treated rats.
Diabetes mellitus is associated with abnormalities of renal hemodynamics and renal electrolyte metabolism, which may contribute to the complications of the disease. The kallikrein-kinin system has been proposed as a contributor to the regulatory control of blood pressure, renal blood flow, and excretion of sodium and water (Levinsky 1979; Carretero and Scicli 1980; Margolius 1983 ). Studies suggest that impaired renal kallikrein and kinins system is relevant to hypertensive and renal diseases (hayfield and Margolius 1983), and diabetes mellitus (Jaffa et al. 1987 ; Harvey et al. 1990 ). Mayfield et al. (1985) reported that renal levels and excretion of immunoreactive kallikrein and kallikrein-like esterase activity are reduced in streptozotocin-induced diabetic rats, and this reduction precedes the onset of systemic hypertension in this model. Hayashi et al. (1983) also reported similar findings. However, the mechanism by which the altered renal kallikreinkinin system is involved in the development of renal impairments in diabetic rats, has not been addressed. In addition, recent studies demonstrated that reduction of glomerular capillary hypertension in diabetic rats by angiotensin converting enzyme inhibitors retarded the subsequent glomerular structure injury and proteinuria (Zats et al. 1986; Fabris et al. 1991) . Since angiotensin converting enzyme is identical with kininase II, responsible for degradation of bradykinin, the biological action of such converting enzyme inhibitors could be due to bradykinin potentiation (Johnston et al. 1981) . So far, it has been unclear whether the kallikrein-kinin system could be involved in the renoprotective effect of angiotensin converting enzyme inhibitors.
In the present study, we determined the excretion of urinary total and active kallikrein in Wistar-Kyoto rats made diabetic by streptozotocin and also evaluated the effect of captopril, an inhibitor of angiotensin converting enzyme, on urinary total and active kallikrein excretion, urine protein excretion and renal function in streptozotocin-induced diabetic rats to assess possible roles of the renal kallikrein-kinin system in the development of diabetic renal impairments.
MATERIALS AND METHODS
Experiments were performed in 8-week-old male normotensive Wistar-Kyoto rats (WKY) (Charles River Japan, Atsugi). The right kidney was removed via a flank incision under light ether anesthesia. One week after uninephrectomy, the rats were intraperitoneally injected with streptozotocin at a dose of 45 mg/kg (Sigma Chemical Co., St. Louis, MO, USA), dissolved in 10 mM citrate buffer (pH 4.5) just before use, and vehicle alone as non diabetic controls. Urine was tested to document glycosuria at 3-4 days after streptozotocin administration. Only the rats with massive glycosuria (a urine glucose concentration>500 mg/100 ml) were employed for the experiment. The rats were fed on standard rat chows (Funabashi farm, Chiba) and had free access to tap water. One week after streptozotocin administration (at 10 weeks of age), baseline measurements of systolic blood pressure, urine protein excretion and urinary kallikrein excretion were performed. The diabetic rats were randomly allocated to receive captopril at a dose of 50 mg/kg/day (Sankyo Co., Tokyo), or vehicle treatment. Each group had 7 rats. Captopril was dissolved in drinking water. The concentration of captopril in the drinking water was adjusted every week after measuring fluid intake and body weight. All rats were maintained in a humidity-and temperature-controlled room during the study. For the collection of 24-hr urine samples to determine urine volume, urinary sodium excretion, urine protein excretion, and urinary total and active kallikrein excretion, each rat was in a metabolic cage devised to prevent feces and urine contact (Sugiyamagen, Tokyo) at 9 weeks and 10 weeks of age and then every 4 weeks up to 22 weeks of age. Urine was collected into vessels chilled at 4°C and kept at -20°C until assay. Systolic blood pressure was recorded by indirect new tail cuff method (VEDA UR 1000, Ueda Industries Co., Tokyo) without anesthesia (Ikeda et al. 1991 ). The systolic blood pressure measurement obtained with this apparatus correlated well with direct systolic blood pressure (Ikeda et al. 1991) . At the age of 22 weeks, the rats were killed by decapitation and trunk blood was collected in polyethylene tubes for determination of the blood urea nitrogen and serum creatinine levels.
Active kallikrein in urine was measured by its kininogenase activity (kinin-releasing capability) using the method of Abe et al. (1979) . Briefly, samples of urine was incubated with purified bovine serum low molecular weight kininogen as substrate in the presence of 1-10 phenanthroline (3 mmol/liter) and EDTA (30 mmol/liter) to inhibit kininases. The samples were incubated at 37°C for 20 min and the reaction was stopped by heating in a boiling water bath. Then the generated kinins were radioimmunologically measured by a modification of the method of Carretero et al. (1976) . Kallikrein activity is expressed as an amount of kinin per ml urine. Total kallikrein was determined by measuring the kininogenase activity in samples after inactive kallikrein had been activated with trypsin (Yasujima et al. 1986 ). In order to activate the inactive kallikrein, 10 pl samples were incubated with 2pg trypsin for 30 min at 37°C. The reaction was stopped by adding 100 ,ug soybean trypsin inhibitor (SBTI). The mixture was incubated for more than 2 hr at room temperature. Kininogenase activity was then measured as described above. In the previous study (Yasujima et al. 1986 ), we found that the optimal amount of trypsin to activate urinary inactive kallikrein was 0.2pg/pl in pooled rat urine collected from 10 normal rats. The dose of SBTI used completely inhibited the kininogenase activity of trypsin used in these experiments. Furthermore, we confirmed that the doses of trypsin and SBTI used in these experiments did not affect the radioimmunoassay of kinins. The reproducibility of the assay method of active and total kallikrein employed in this experiment has been previously described (Yasujima et al. 1986 ).
Statistical analysis of the data between groups was performed by two-way analysis of variance for repeated measurements. Statistically significant difference on each day was examined by Student's t-test (between groups). Values are given in terms of mean±s.E.
RESULTS
As shown in Table 1 , there were no significant differences in body weight, systolic blood pressure, urine volume, urinary sodium excretion and urine protein excretion before the induction of diabetes mellitus. Streptozotocin induced a marked elevation of blood sugar (439.0±57.0 mg/ 100 ml compared to 144.7± 6.2 mg/ 100 ml at 10 weeks of age, p <0.05; 564.8± 10.2 mg/ 100 ml compared to 120.2 + 4.9 mg/ 100 ml at 22 weeks of age, p <0.05) and a decrease in body weight. Significant differences in urine volume, urine protein excretion and blood urea nitrogen (37.2 + 2.5 mg/ 100 ml compared to 19.6 + 0.6 mg/ 100 ml at 22 weeks of age, p <0.05) were also found between rats receiving streptozotocin and vehicle- injected controls, whereas streptozotocin did not induce any significant change in serum creatinine (0.64±0.05 mg/ 100 ml compared to 0.58±0.06 mg/ 100 ml at 22 weeks of age, n.s.). On the contrary, no significant differences in systolic blood pressure and urinary sodium excretion were found between these two groups of rats. Table 2 shows the urinary excretion of total and active kallikrein, and the ratio of active to total kallikrein in the rat before and after the injection of streptozotocin or vehicle. The administration of streptozotocin induced a significant decrease in active kallikrein, but not in total kallikrein, resulting in a significant decrease in the ratio of active to total kallikrein. The reduction of urinary active kallikrein excretion and the ratio of active to total kallikrein were preceded by the increased urine protein excretion.
Figs. 1 and 2 show body weight, systolic blood pressure, urine volume, urinary sodium excretion and urine protein excretion in streptozotocin-injected rats before and during the administration of captopril or vehicle. As shown in Figs. 1 and 2, there were no significant differences in body weight, systolic blood pressure, urine volume, urinary sodium excretion and urine protein excretion before the administration of captopril or vehicle. Captopril did not induce any significant change in blood sugar (433.5±38.2 mg/ 100 ml compared to 439.0± 57.0 mg/ 100 ml at 10 weeks of age, n.s.; 510.0±30.8 mg/ 100 ml compared to 564.8 + 10.2 mg/ 100 ml at 22 weeks of age, n.s.). Captopril attenuated the elevation of systolic blood pressure in streptozotocin-treated rats throughout the study period (Fig. 1) . As shown in Fig. 2 , significant differences in urine protein excretion and blood urea nitrogen (24.9 + 2.8 mg/100 ml compared to 37.2 + 2.5 mg/ 100 ml at 22 weeks of age, p <0.05) were found between captopril-and vehicle-treated rats, whereas no significant differences in urine volume, urinary sodium excretion and serum creatinine (0.73 + 0.12 mg/ 100 ml compared to 0.64 + 0.05 mg/ 100 ml at 22 weeks of age, n.s.) were found between these two groups of rats. Fig. 3 shows the urinary excretion of total and active kallikrein, and the ratio of active to total kallikrein in streptozotocin-injected rats before and during the administration of captopril or vehicle. Captopril did not induce any significant changes in these parameters of kallikrein in streptozotocin-treated rats.
DISCUSSION
Urinary kallikrein excretion was found to be lower in streptozotocin-diabetic rats than in control rats. Our studies extended this knowledge by demonstrating that in streptozotocin-diabetic rats with uninephrectomy urinary active kallikrein and the ratio of urinary active to total kallikrein excretion were lower than in control rats and these reduction were preceded by renal impairments. In addition, we tested the hypothesis that decreased activity of renal kallikrein could be involved in the development of renal impairments in this model of rats. Administration of captopril, an inhibitor of angiotensin converting enzyme and kininase II, significantly attenuated the development of renal impairments evaluated by urine protein excretion, but it had no effects on parameters of urinary kallikrein excretion.
Studies have shown that there is an inactive form of kallikrein in rat urine (Omata et al. 1982; Yamada and Erdos 1982; Nishimura et al. 1983 ), although it is not known whether inactive kallikrein is a proenzyme or an enzyme inhibitor complex. The ratio of active to total kallikrein in the urine of streptozotocindiabetic rats is reduced compared to that in non diabetic control rats as reported previously (Jaffa et al. 1987 ). The significant decrease in active kallikrein whereas total kallikrein unchanged, suggests a suppressed mechanism of the activation of renal kallikrein. Jaffa et al. (1987) demonstrated that the reduction of active kallikrein in streptozotocin-diabetic rats is due to impaired renal prokallikrein activation, rather than an increase in the level of an inhibitor of active kallikrein. In addition, they showed that insulin modulates renal kallikrein production, activation and excretion. Although it has been reported that the reduced active kallikrein in streptozotocin-diabetic rats precedes the onset of systemic hypertension (Hayashi et al. 1983; Mayfield et al. 1985 ), we could not show a significant difference in systolic blood pressure between streptozotocindiabetic rats and non diabetic control rats. At the moment, we have no definite explanation for the discrepancy between the present results and previous data reporting the significant increase in blood pressure in streptozotocin-diabetic rats, but it may be due to the differences in methods employed to measure systolic blood pressure, species of the animals and experimental design. It is interesting to note that the increased excretion of urine protein measured as an index of renal impairments, precedes the reduction of urinary active kallikrein excretion and the ratio of active to total kallkrein. This may suggest that diabetic renal impairments could be followed by the reduction in active kallikrein, whereas its exact mechanism remains to be clarified.
The response of urinary kallikrein to captopril treatment in streptozotocindiabetic rats, suggests that captopril does not modulate urinary kallikrein activation and the renoprotective effects of captopril may be independent of the activation of renal kallikrein.
Our previous data demonstrated that inhibitors of angiotensin converting enzyme and kininase II including captopril, induced a significant increase in urinary kallikrein excretion in normotensive rats (Yasujima et al. 1984) . In the present study, we demonstrated unchanged urinary active kallikrein excretion and ratio of active to total kallikrein in streptozotocindiabetic rats with captopril. However, it might be unreasonable to deny the enhanced kinin levels, active peptides of renal kallikrein-kinin system, associated with the inhibition of kinin degradation with captopril, although unfortunately we did not measure urinary kinin excretion during the treatment with captopril in the present study. The results of this study show that the inhibition of angiotensin converting enzyme and kininase II alter the development of renal impairments in streptozotocin-diabetic rats, and are unlikely to support the hypothesis that renal kallikrein is acting as a protective mechanism for reducing the development of diabetic renal impairments. Captopril did not induce any changes in urine volume, urinary sodium excretion and parameters of urinary kallikrein excretion in streptozotocin-diabetic rats, whereas it significantly lowered systolic blood pressure and urine protein excretion. Taken together, the pathophysiological role of renal kallikrein remains to be determined, and the reduced activity of renal kallikrein in streptozotocin-diabetic rats appears to be independent of the mechanism of renal impairments.
In conclusion, this study clearly demonstrates that in streptozotocin-diabetic rats, renal kallikrein activity is reduced compared to that in age-matched control rats. However, the pathophysiological relevance of the reduced renal kallikreinkinin system in the early development of diabetic renal impairments remains to be determined.
